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Meningococcal C Polysaccharide Vaccine Induces Immunologic Hyporesponsiveness in Adults: Additional Data
To the Editor-Richmond et al. [1] reported that the immune response to meningococcal polysaccharide vaccine (MPV) for serogroup C is suppressed in adults who have been previously immunized with the vaccine. The immune response to MPV for serogroup C has been shown to be suppressed in children !2 years old who had received a primary series of this vaccine [2, 3] . However, the vaccine is not licensed for children !2 years old and should not be used for this age group except under special circumstances, such as an outbreak setting [4] . There are no data published that investigate this phenomenon in adults who have received successive doses of MPV at both the recommended dose and at the recommended interval (3-5 years) for revaccination [4] . The opportunity to investigate this issue exists at Aventis Pasteur, since all employees who enter the manufacturing site for MPV are required to receive MPV at the recommended dose every 3-5 years.
We evaluated serum antibody responses to serogroup C for 51 consecutive individuals who had received a booster dose of quadrivalent MPV (Menomune-A/C/Y/W-135) ∼5 years after either 1 dose (13 individuals) or 2 successive doses (38 individuals) at an interval of ∼5 years (table 1). The antibody concentration was determined by an ELISA [5] done on serum samples collected just prior to immunization and ∼28 days after immunization. The results showed a pre-booster vaccination level of IgG against serogroup C of 7.8 mg/mL and a post-booster vaccination level of 17.3 mg/mL ( ). Re-P p .006 sults also showed a pre-booster vaccination level of IgM of 0.48 mg/mL and a post-booster vaccination level of 1.6 mg/mL ( ). These responses represent 2.2-fold and 3.4-fold in-P ! .001 creases for IgG and IgM, respectively. In addition, an IgG antibody concentration of 11 mg/mL was present in 94% of persons both before and after they had received a booster vaccine. An IgG antibody concentration 12 mg/mL was present in 86% of persons before they had received a booster vaccine and in 94% after the booster vaccine.
These data demonstrate that a substantial and significant polyclonal immune response to serogroup C occurs after a booster dose in individuals who had received 1 or 2 prior doses of MPV at the recommended interval.
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